• +1-646-491-9876
    • +91-20-67278686

    Search

    Otitis Media-Pipeline Review H2 2017

    Otitis Media-Pipeline Review H2 2017

    • Report Code ID: RW0001881454
    • Category Life Sciences
    • No. of Pages 72
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Otitis Media-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media-Pipeline Review H2 2017 provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

    Otitis media (OM) is any inflammation of the middle ear the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain difficulty sleeping loss of balance fever headache and loss of appetite. Risk factors include age seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Otitis Media-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical and Discovery stages are 2 3 2 3 and 3 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.

    Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Otitis Media-Overview
    Otitis Media-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Otitis Media-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Otitis Media-Companies Involved in Therapeutics Development
    ContraFect Corp
    GlaxoSmithKline Plc
    Lee's Pharmaceutical Holdings Ltd
    Madam Therapeutics BV
    Merck & Co Inc
    MerLion Pharmaceuticals Pte Ltd
    Novus Therapeutics Inc
    Otonomy Inc
    Yuhan Corp
    Otitis Media-Drug Profiles
    (cholesteryl palmitate + colfosceril palmitate)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (dexamethasone acetate + piperacillin sodium + tazobactam sodium)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    betahistine dihydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-303-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CF-309-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ciprofloxacin hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    finafloxacin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2189242A-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pazufloxacin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PCL-1440-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pneumococcal (23-valent) vaccine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Otitis Media-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solithromycin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Otitis Media-Dormant Projects
    Otitis Media-Product Development Milestones
    Featured News & Press Releases
    Jun 22 2017 Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute Otitis Media with Tympanostomy Tubes
    Jun 02 2017 Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
    May 12 2017 Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
    Nov 02 2016 Otonomy Announces Assignment of J Code for OTIPRIO
    Oct 07 2016 Otonomy Holds Investor and Analyst Day and Provides Corporate Update
    Oct 04 2016 Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes
    Sep 15 2016 Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes
    May 20 2016 Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO
    May 16 2016 Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
    Mar 18 2016 Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology
    Mar 03 2016 Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
    Mar 02 2016 Otonomy Announces Commercial Availability of OTIPRIO
    Dec 11 2015 Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
    Nov 03 2015 Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
    Sep 24 2015 Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Otitis Media H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Otitis Media-Pipeline by ContraFect Corp H2 2017
    Otitis Media-Pipeline by GlaxoSmithKline Plc H2 2017
    Otitis Media-Pipeline by Lee's Pharmaceutical Holdings Ltd H2 2017
    Otitis Media-Pipeline by Madam Therapeutics BV H2 2017
    Otitis Media-Pipeline by Merck & Co Inc H2 2017
    Otitis Media-Pipeline by MerLion Pharmaceuticals Pte Ltd H2 2017
    Otitis Media-Pipeline by Novus Therapeutics Inc H2 2017
    Otitis Media-Pipeline by Otonomy Inc H2 2017
    Otitis Media-Pipeline by Yuhan Corp H2 2017
    Otitis Media-Dormant Projects H2 2017

    List of Figures

    Number of Products under Development for Otitis Media H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    ContraFect Corp
    GlaxoSmithKline Plc
    Lee's Pharmaceutical Holdings Ltd
    Madam Therapeutics BV
    Merck & Co Inc
    MerLion Pharmaceuticals Pte Ltd
    Novus Therapeutics Inc
    Otonomy Inc
    Yuhan Corp

    Request for Sample

    Report Url https://www.reportsweb.com//otitis-media-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//otitis-media-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//otitis-media-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments